Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Should everyone over 50 be taking aspirin?

17.06.2005


For and against: Aspirin for everyone over 50? BMJ Volume 330, pp 1440-3



Experts go head to head in this week’s BMJ over whether everyone over 50 should take a daily aspirin to reduce their risk of heart attacks and strokes. Peter Elwood and colleagues at Cardiff University believe that the evidence now supports more widespread use of aspirin, and there needs to be a strategy to inform the public and enable older people to make their own decision.

As a general rule, daily aspirin is given only to people whose five year risk of a vascular event, such as a heart attack or stroke, is 3% or more. The authors show that, by age 50, 80% of men and 50% of women reach this level of risk and they suggest that 90-95% of the population could take low dose aspirin without problems. Evidence is also growing that regular aspirin may reduce cancer and dementia.


"The possibility that a simple, daily, inexpensive low dose pill would achieve a reduction in vascular events, and might achieve reductions in cancer and dementia without the need for screening, deserves serious consideration," they write. "Although we judge that aspirin should be taken from around 50 years, we insist that the general public should be well informed and the final decision should lie with each person."

But Colin Baigent of the Oxford Radcliffe Infirmary warns that it would be unwise to adopt such a policy, whatever age threshold is chosen, until we are sure that older patients will derive net benefit from it.

Based on data for 55-59 year olds, aspirin prevents around two first heart attacks per 1000 population each year. However, this benefit does not outweigh the expected risk of a major gastrointestinal bleed at age 60 (1-2 per 1000 per year).

"In my view, we should not contemplate an age threshold approach to primary prevention with aspirin until we have much better evidence of its benefits in older people," he says. We therefore need further randomised trials comparing low dose aspirin with placebo.

"A recommendation that aspirin be used for primary prevention of vascular disease in unselected people over a certain age could result in net harm, and we must have very good evidence to the contrary before instituting such a policy," he concludes.

Emma Dickinson | EurekAlert!
Further information:
http://www.bmj.com

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>